[go: up one dir, main page]

MA33538B1 - Nouveaux antagonistes pyrimidine et triazine de l'hepcidine - Google Patents

Nouveaux antagonistes pyrimidine et triazine de l'hepcidine

Info

Publication number
MA33538B1
MA33538B1 MA34652A MA34652A MA33538B1 MA 33538 B1 MA33538 B1 MA 33538B1 MA 34652 A MA34652 A MA 34652A MA 34652 A MA34652 A MA 34652A MA 33538 B1 MA33538 B1 MA 33538B1
Authority
MA
Morocco
Prior art keywords
hepsidin
triazine
pyrimidine antagonists
new pyrimidine
anemia
Prior art date
Application number
MA34652A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Otto Geisser
Franz Dürrenberger
Susanna Burckhardt
Wilm Buhr
Felix Funk
Julia Marie Bainbridge
Vincent Anthony Corden
Stephen Martin Courtney
Tara Davenport
Stefan Jaeger
Mark Peter Ridgill
Mark Slack
Christopher John Yarnold
Wei Tsung Yau
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41490366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33538(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of MA33538B1 publication Critical patent/MA33538B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux antagonistes de l'hepcidine de formule (I), des compositions pharmaceutiques les comprenant ainsi que leur utilisation comme médicament, en particulier pour le traitement de troubles du métabolisme du fer, comme en particulier les maladies de carence en fer et les anémies, en particulier les anémies en liaison avec des maladies inflammatoires chroniques (ACD : anémie de maladie chronique et AI : anémie d'inflammation).
MA34652A 2009-09-02 2012-02-27 Nouveaux antagonistes pyrimidine et triazine de l'hepcidine MA33538B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09169286 2009-09-02
PCT/EP2010/062708 WO2011026835A1 (fr) 2009-09-02 2010-08-31 Nouveaux antagonistes pyrimidine et triazine de l'hepcidine

Publications (1)

Publication Number Publication Date
MA33538B1 true MA33538B1 (fr) 2012-08-01

Family

ID=41490366

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34652A MA33538B1 (fr) 2009-09-02 2012-02-27 Nouveaux antagonistes pyrimidine et triazine de l'hepcidine

Country Status (21)

Country Link
US (1) US20120202806A1 (fr)
EP (1) EP2473486B2 (fr)
JP (1) JP2013503833A (fr)
KR (1) KR20120061055A (fr)
CN (1) CN102482232A (fr)
AR (1) AR077999A1 (fr)
AU (1) AU2010291318A1 (fr)
BR (1) BR112012008109A2 (fr)
CA (1) CA2769553A1 (fr)
CL (1) CL2012000591A1 (fr)
CR (1) CR20120097A (fr)
DO (1) DOP2012000057A (fr)
EA (1) EA201200402A1 (fr)
ES (1) ES2554855T3 (fr)
IL (1) IL218253A0 (fr)
MA (1) MA33538B1 (fr)
MX (1) MX2012002626A (fr)
SG (1) SG178984A1 (fr)
TN (1) TN2012000045A1 (fr)
TW (1) TW201113272A (fr)
WO (1) WO2011026835A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
DE102010002558A1 (de) * 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
WO2012012528A1 (fr) 2010-07-20 2012-01-26 Vestaron Corporation Triazines et pyrimidines insecticides
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
AP3907A (en) 2011-09-27 2016-11-23 Novartis Ag 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
JP2014237590A (ja) * 2011-09-30 2014-12-18 アステラス製薬株式会社 ２−（ピリジン−２−イル）ピリミジン−４−アミン化合物又はその塩
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
IN2014KN02601A (fr) 2012-04-24 2015-05-08 Vertex Pharma
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014105952A2 (fr) * 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibiteurs du complexe usp1/uaf1 désubiquitinase et leurs utilisations
JP6120311B2 (ja) * 2013-02-12 2017-04-26 学校法人銀杏学園 ポリフェノール化合物
PT2970218T (pt) 2013-03-12 2019-03-01 Vertex Pharma Inibidores de adn-pk
CA2903979A1 (fr) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
WO2015036563A1 (fr) 2013-09-16 2015-03-19 Bayer Pharma Aktiengesellschaft Trifluorométhylpyrimidones disubstituées et leur utilisation comme antagonistes du ccr2
ES2802296T3 (es) 2013-10-17 2021-01-18 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
AR110770A1 (es) 2017-01-23 2019-05-02 Cadent Therapeutics Inc Moduladores del canal de potasio
US10172856B2 (en) 2017-04-06 2019-01-08 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine H4 modulators
MX2020002347A (es) 2017-08-31 2020-10-28 Basf Se Uso de principios activos refrescantes fisiologicos y agentes que contienen dichos principios activos.
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators
BR112021006222A2 (pt) * 2018-11-30 2021-07-06 Otsuka Pharma Co Ltd compostos heterocíclicos para o tratamento de epilepsia
WO2021222359A1 (fr) * 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thiénopyrimidines servant d'inhibiteurs de la ferroportine
KR20230007441A (ko) 2020-04-28 2023-01-12 글로벌 블러드 테라퓨틱스, 인크. 페로포르틴 억제제로서의 시클로알킬 피리미딘
WO2021222483A1 (fr) * 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Méthodes d'utilisation de pyrimidines en tant qu'inhibiteurs de la ferroportine
CN112028838B (zh) * 2020-08-04 2022-07-01 精华制药集团南通有限公司 一种2-乙氧基-5-氟尿嘧啶杂质的制备方法
CN113683596B (zh) * 2021-08-17 2023-02-10 上海应用技术大学 一种嘧啶类端锚聚合酶2抑制剂及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489591A (en) * 1992-02-28 1996-02-06 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US7166448B1 (en) 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
TR201806761T4 (en) 2001-05-25 2018-06-21 Inst Nat Sante Rech Med THE USE OF ALL IN THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF IRON HOMEOSTASIS DISORDERS.
EP1397142A4 (fr) 2001-06-19 2004-11-03 Bristol Myers Squibb Co Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
JP4769418B2 (ja) * 2002-01-02 2011-09-07 アクテリオン ファーマシューティカルズ リミテッド 新規なアルカンスルホンアミド類
TW200407315A (en) 2002-04-23 2004-05-16 Sankyo Co Pyrimidine derivatives
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
WO2004058044A2 (fr) 2002-11-19 2004-07-15 Drg International, Inc. Methode diagnostique pour maladies par criblage d'hepcidine dans des tissus, du sang ou des fluides corporels humains ou animaux et utilisations therapeutiques
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
ATE485824T1 (de) 2004-04-13 2010-11-15 Icagen Inc Polycyclische pyrimidine als kaliumionenkanal- modulatoren
US7723063B2 (en) 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
CA2579472A1 (fr) * 2004-09-14 2006-03-23 The Genetics Company, Inc. Derives d'hydrazone et leur utilisation comme inhibiteurs de la beta-secretase
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0503962D0 (en) * 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
WO2006116301A1 (fr) * 2005-04-22 2006-11-02 The Johns Hopkins University Composes neuroprotecteurs pour traiter les neuropathies optiques
US20060293343A1 (en) 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
US7534764B2 (en) 2005-06-29 2009-05-19 The Regents Of The University Of California Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
US8258129B2 (en) 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
CA2663581C (fr) 2006-09-21 2016-03-01 Alnylam Pharmaceuticals, Inc. Compositions et procedes servant a inhiber l'expression du gene hamp
US9987277B2 (en) 2006-10-04 2018-06-05 Janssen Sciences Ireland Uc Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C
WO2008088727A2 (fr) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Antagonistes du récepteur de l'endothéline
AU2008214386B2 (en) 2007-02-02 2013-09-19 Amgen Inc Hepcidin and hepcidin antibodies
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
CL2008000666A1 (es) 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
AR065785A1 (es) 2007-03-19 2009-07-01 Xenon Pharmaceuticals Inc Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro
PT2139882E (pt) 2007-03-23 2014-01-30 Amgen Inc Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k)
WO2008121861A2 (fr) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Composés à base de pyrazole et de pyrrole utiles dans le traitement de troubles du métabolisme du fer
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
CA2688547A1 (fr) 2007-06-05 2008-12-11 Xenon Pharmaceuticals, Inc. Composes aromatiques et heteroaromatiques utiles dans le traitement de troubles du metabolisme du fer
NZ582485A (en) 2007-07-17 2012-05-25 Rigel Pharmaceuticals Inc Cyclic amine substituted pyrimidinediamines as pkc inhibitors
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
CN101784531B (zh) 2007-08-30 2013-05-01 陶氏益农公司 2-(取代的苯基)-6-氨基-5-烷氧基、硫代烷氧基和氨基烷基嘧啶-4-羧酸衍生物及其作为除草剂的用途
JP2010539969A (ja) 2007-10-02 2010-12-24 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） ヒトヘプシジンに対して特異性を有する抗原結合タンパク質
CL2008003190A1 (es) 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
US20110124649A1 (en) * 2007-11-09 2011-05-26 The Johns Hopkins University Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
CN101932583A (zh) * 2007-12-19 2010-12-29 沃泰克斯药物股份有限公司 用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类
WO2009093981A1 (fr) * 2008-01-23 2009-07-30 S Bio Pte Ltd Composés de triazine comme inhibiteurs de la kinase
JP4613248B2 (ja) 2008-02-08 2011-01-12 株式会社資生堂 美白剤及び皮膚外用剤
EP2257539B1 (fr) * 2008-03-18 2014-09-10 Merck Sharp & Dohme Corp. 4-hydroxypyrimidine-5-carboxamides substitués
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina

Also Published As

Publication number Publication date
BR112012008109A2 (pt) 2019-09-24
MX2012002626A (es) 2012-04-20
EA201200402A1 (ru) 2012-08-30
EP2473486A1 (fr) 2012-07-11
CR20120097A (es) 2012-09-03
EP2473486B1 (fr) 2015-10-28
DOP2012000057A (es) 2012-08-31
AU2010291318A1 (en) 2012-03-01
IL218253A0 (en) 2012-04-30
SG178984A1 (en) 2012-04-27
JP2013503833A (ja) 2013-02-04
CN102482232A (zh) 2012-05-30
CL2012000591A1 (es) 2012-08-03
TN2012000045A1 (en) 2013-09-19
KR20120061055A (ko) 2012-06-12
TW201113272A (en) 2011-04-16
US20120202806A1 (en) 2012-08-09
AR077999A1 (es) 2011-10-05
EP2473486B2 (fr) 2021-09-22
CA2769553A1 (fr) 2011-03-10
WO2011026835A1 (fr) 2011-03-10
ES2554855T3 (es) 2015-12-23

Similar Documents

Publication Publication Date Title
MA33538B1 (fr) Nouveaux antagonistes pyrimidine et triazine de l'hepcidine
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
BR112013020916A2 (pt) compostos de fórmula geral, composição e preparação combinada
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
MA38276A1 (fr) Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
GB0625648D0 (en) Compounds
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar